IGF-1 LR3 vs Kisspeptin-10
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
IGF-1 LR3
IGF-1 LR3 (Long Arg3 IGF-1) is a synthetic analogue of Insulin-like Growth Factor 1 with an amino acid substitution at position 3 and a 13-amino acid N-terminal extension. These modifications prevent binding to IGF-binding proteins (IGFBPs), dramatically extending its half-life from ~12 minutes (native IGF-1) to approximately 20–30 hours. IGF-1 LR3 is widely used in research for its ability to promote cellular growth, protein synthesis, hyperplasia, and nutrient uptake into muscle tissue.
Full profileKisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profile| IGF-1 LR3 | Kisspeptin-10 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent) | KP-10, Metastin(112-121), KISS1R agonist |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol) | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) |
| Administration | Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols) | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) |
| Key side effects | Hypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint pain | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: IGF-1 LR3 is research-stage, while Kisspeptin-10 is fda-approved.
- Administration: IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols); Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
- Frequency: IGF-1 LR3 is typically Once daily post-workout, on training days only (common protocol); Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
How each works
IGF-1 LR3
In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.